Landmark trial
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
Coles CE, Haviland JS, Kirby AM, et al.
DoseLab summary
Results of the UK IMPORT HIGH trial of dose-escalated simultaneous integrated boost radiotherapy. Citation as given in the eviQ reference list; not yet checked against the journal.
Why this is useful
Phase 3 trial of a simultaneous integrated boost; the source of the contralateral breast mean-dose limits in DoseLab's whole breast table.
Reference details
- Title
- Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
- Authors / organization
- Coles CE, Haviland JS, Kirby AM, et al.
- Publication / protocol
- Lancet. 2023;401(10394):2124–2137
- Version
- Pending verification
- Year
- 2023
- DOI
- Pending verification
- Disease sites
- Breast
- Topics
- Breast, SIB, Boost, Landmark trial, Dose Constraints
- Fractionation context
- Whole breast with simultaneous integrated boost
- Last reviewed by DoseLab
- Pending verification